A Study of Prophylactic Value of Antiparkinsonian Drug

The present prospective study is conducted to determine the prophylactic value of antiparkinsonian drug (A.P.) at the time of initiation of antipsychotic therapy. Seventy patients were selected who fulfilled the selection criteria. Thirty five patients received antipsychotic drugs alone (Group A), while another thirty five patients received A.P. drugs concurrently with antipsychotic drugs (Group B.) These patients were assessed weekly for 4 weeks for any extra pyramidal symptoms (E.P.S.). There was no statistically significant difference between E.P.S. scores of the two groups in different weeks. The difference in percentage of patients who developed E.P.S. in different weeks in both the groups was statistically non-significant (p<0.05). None of the female subjects developed E.P.S. in either group.